MARKET

ORGS

ORGS

Orgenesis Inc
NASDAQ
0.5071
+0.0031
+0.62%
After Hours: 0.5120 +0.0049 +0.97% 18:00 04/26 EDT
OPEN
0.5020
PREV CLOSE
0.5040
HIGH
0.5203
LOW
0.4925
VOLUME
24.52K
TURNOVER
0
52 WEEK HIGH
1.500
52 WEEK LOW
0.2500
MARKET CAP
17.41M
P/E (TTM)
-0.2657
1D
5D
1M
3M
1Y
5Y
ORGENESIS INC FILES FOR MIXED SHELF OF UP TO $100 MLN- SEC FILING
Reuters · 4d ago
Weekly Report: what happened at ORGS last week (0415-0419)?
Weekly Report · 4d ago
BRIEF-Orgenesis Board Says Financial Statements For Qtrs Ended March 31, 2023, June 30, 2023, Sept 30, 2023, To No Longer Be Relied Upon
Orgenesis Board Says Financial Statements For Qtrs Ended March 31, 2023, Should No Longer Be Relied Upon. Orgenesis Inc says financial statements should no longer be relied on. The company says the statements are for the period of March 31 to September 30, 20 23.
Reuters · 04/15 22:22
ORGENESIS INC - LOOKING FORWARD, OUR FIRST MAJOR STEP IN TRANSFORMATION WAS RECENT TRANSACTION TO REGAIN 100% OWNERSHIP OF OCTOMERA
Reuters · 04/15 21:07
Press Release: Orgenesis Provides Year End -2-
Undertake no obligation to revise or update any forward-looking statement for any reason. Orgenesis has a total of 4,076 million dollars in cash and cash equivalents as of December 31, 2018. The company has a long-term target of $5,000 million. The Company has no debt.
Dow Jones · 04/15 21:07
ORGENESIS- BOARD DETERMINED CO'S FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, 2023, JUNE 30, 2023, SEPT 30, 2023, SHOULD NO LONGER BE RELIED UPON
Reuters · 04/15 21:02
Orgenesis Provides Year End Business Update
Barchart · 04/15 16:07
Weekly Report: what happened at ORGS last week (0408-0412)?
Weekly Report · 04/15 10:32
More
About ORGS
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Webull offers Orgenesis Inc stock information, including NASDAQ: ORGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORGS stock methods without spending real money on the virtual paper trading platform.